📊 VIR Key Takeaways
Is Vir Biotechnology, Inc. (VIR) a Good Investment?
Vir Biotechnology faces an unsustainable financial crisis with operating losses of -$479.3M on minimal $68.6M revenue, burning through $396.6M in free cash flow annually. With only $232.2M in cash and no debt, the company has less than 7 months of runway at current burn rates, forcing imminent capital dilution or operational restructuring. While modest YoY loss improvement (+16.1%) and strong balance sheet liquidity provide temporary relief, the fundamental disconnect between revenue and operating costs indicates structural unprofitability.
Why Buy Vir Biotechnology, Inc. Stock? VIR Key Strengths
- Strong liquidity position with 5.54x current ratio and 5.54x quick ratio
- No long-term debt burden (0.00x debt/equity ratio) reduces financial leverage risk
- Slight YoY improvement in net loss (-16.1%) and EPS (-17.5%) suggests operational course correction attempts
VIR Stock Risks: Vir Biotechnology, Inc. Investment Risks
- Unsustainable cash burn of $396.6M annually against $232.2M cash reserves creates imminent solvency pressure
- Revenue of only $68.6M cannot support $479.3M operating losses, indicating fundamental business model dysfunction at current stage
- Operating margin of -699.2% demonstrates massive operating losses with no clear profitability pathway visible in current financial trajectory
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to cash depletion
- Quarterly revenue growth trajectory and achievement of commercial milestones
- Operating expense reduction initiatives and their impact on loss improvement velocity
Vir Biotechnology, Inc. (VIR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.54x current ratio provides a solid financial cushion.
VIR Profit Margin, ROE & Profitability Analysis
VIR vs Healthcare Sector: How Vir Biotechnology, Inc. Compares
How Vir Biotechnology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vir Biotechnology, Inc. Stock Overvalued? VIR Valuation Analysis 2026
Based on fundamental analysis, Vir Biotechnology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vir Biotechnology, Inc. Balance Sheet: VIR Debt, Cash & Liquidity
VIR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vir Biotechnology, Inc.'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-4.59 indicates the company is currently unprofitable.
VIR Revenue Growth, EPS Growth & YoY Performance
VIR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $240.0K | -$163.1M | $-1.17 |
| Q2 2025 | $1.2M | -$111.0M | $-0.80 |
| Q1 2025 | $3.0M | -$65.3M | $-0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vir Biotechnology, Inc. Dividends, Buybacks & Capital Allocation
VIR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vir Biotechnology, Inc. (CIK: 0001706431)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VIR
What is the AI rating for VIR?
Vir Biotechnology, Inc. (VIR) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VIR's key strengths?
Claude: Strong liquidity position with 5.54x current ratio and 5.54x quick ratio. No long-term debt burden (0.00x debt/equity ratio) reduces financial leverage risk.
What are the risks of investing in VIR?
Claude: Unsustainable cash burn of $396.6M annually against $232.2M cash reserves creates imminent solvency pressure. Revenue of only $68.6M cannot support $479.3M operating losses, indicating fundamental business model dysfunction at current stage.
What is VIR's revenue and growth?
Vir Biotechnology, Inc. reported revenue of $68.6M.
Does VIR pay dividends?
Vir Biotechnology, Inc. does not currently pay dividends.
Where can I find VIR SEC filings?
Official SEC filings for Vir Biotechnology, Inc. (CIK: 0001706431) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VIR's EPS?
Vir Biotechnology, Inc. has a diluted EPS of $-3.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VIR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vir Biotechnology, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VIR stock overvalued or undervalued?
Valuation metrics for VIR: ROE of -57.2% (sector avg: 15%), net margin of -638.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VIR stock in 2026?
Our dual AI analysis gives Vir Biotechnology, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VIR's free cash flow?
Vir Biotechnology, Inc.'s operating cash flow is $-391.8M, with capital expenditures of $4.8M. FCF margin is -578.5%.
How does VIR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -638.9% (avg: 12%), ROE -57.2% (avg: 15%), current ratio 5.54 (avg: 2).